IMVT
Immunovant, Inc.
NASDAQ · Healthcare · Biotechnology · US
$36.95
−1.86%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$37.97
From 52W high−17.82%
Volume2.94M
Market cap$7.63B
P/E (TTM)—
P/S (TTM)1075.7x
Div yield—
Key dataSep 18, 2026
Open
$37.97
From 52W high
−17.82%
Volume
2.94M
Market cap
$7.63B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−12.7x
P/E (TTM)
—
RSI (14)
36.2
MomentumView details →
1D Return
−1.86%
YTD Return
+45.44%
SummaryUpdated Jun 1, 2026
Immunovant, Inc. (NASDAQ:IMVT) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in New York, New York. The company went public in June 2019 and operates as a subsidiary of Roivant Sciences Ltd. Immunovant focuses on developing innovative monoclonal antibody treatments for autoimmune diseases, with its lead drug candidate batoclimab currently advancing through multiple Phase II clinical trials for various autoimmune conditions.
Similar companies
Latest newsMore news →
Immunovant, Inc. shares reached a new 52-week high of $43.89 during mid-day trading on Tuesday, last trading at $43.71 with a volume of 1,216,514 shares, after closing at $41.82.33d agoImmunovant, Inc. reported its Q1 2026 financial results, with a GAAP net loss of $153.2 million and diluted EPS of -$0.75.46d ago